US 12,458,643 B2
Antidepressant/anxiolytic drug in which PAC1 receptor antagonist is used
Takashi Kurihara, Kagoshima (JP); Ichiro Takasaki, Toyama (JP); Hitoshi Hashimoto, Osaka (JP); Atsuko Hayata, Osaka (JP); and Yusuke Shintani, Osaka (JP)
Assigned to KAGOSHIMA UNIVERSITY, Kagoshima (JP); and OSAKA UNIVERSITY, Osaka (JP)
Appl. No. 17/997,974
Filed by KAGOSHIMA UNIVERSITY, Kagoshima (JP); and OSAKA UNIVERSITY, Osaka (JP)
PCT Filed May 7, 2021, PCT No. PCT/JP2021/017501
§ 371(c)(1), (2) Date Nov. 5, 2022,
PCT Pub. No. WO2021/225161, PCT Pub. Date Nov. 11, 2021.
Claims priority of application No. 2020-082465 (JP), filed on May 8, 2020.
Prior Publication US 2023/0181587 A1, Jun. 15, 2023
Int. Cl. A61K 31/519 (2006.01); A61K 31/4178 (2006.01); A61P 25/22 (2006.01); A61P 25/24 (2006.01)
CPC A61K 31/519 (2013.01) [A61K 31/4178 (2013.01); A61P 25/22 (2018.01); A61P 25/24 (2018.01)] 14 Claims
 
1. A method for treating and/or preventing a disease that is anxiety disorder, stress disorder, and/or depression, comprising administering to a subject in need thereof an effective amount of a compound of formula (I):

OG Complex Work Unit Chemistry
wherein
R1 is a hydrogen atom, a C1-6-alkyl group, a C1-6-alkoxy group, a C2-6-alkenyloxy group, a halogen atom, a C1-6-haloalkyl group, a C1-6-haloalkoxy group, or a substituted or unsubstituted phenyl group; and
R2 is a hydrogen atom, a C1-6-alkyl group, a C1-6-alkoxy group, a C2-6-alkenyloxy group, a halogen atom, a C1-6-haloalkyl group, a C1-6-haloalkoxy group, or a substituted or unsubstituted phenyl group;
or a salt thereof, or a solvate thereof.